Optimal age targeting for pneumococcal vaccination in older adults; a modelling study

Deus Thindwa (), Samuel Clifford, Jackie Kleynhans, Anne Gottberg, Sibongile Walaza, Susan Meiring, Todd D. Swarthout, Elizabeth Miller, Peter McIntyre, Nick Andrews, Zahin Amin-Chowdhury, Norman Fry, Kondwani C. Jambo, Neil French, Samanta Cristine Grassi Almeida, Shamez N. Ladhani, Robert S. Heyderman, Cheryl Cohen, Maria Cristina Cunto Brandileone and Stefan Flasche
Additional contact information
Deus Thindwa: London School of Hygiene & Tropical Medicine
Samuel Clifford: London School of Hygiene & Tropical Medicine
Jackie Kleynhans: National Institute for Communicable Diseases of the National Health Laboratory Service
Anne Gottberg: National Institute for Communicable Diseases of the National Health Laboratory Service
Sibongile Walaza: National Institute for Communicable Diseases of the National Health Laboratory Service
Susan Meiring: National Institute for Communicable Diseases of the National Health Laboratory Service
Todd D. Swarthout: Malawi Liverpool Wellcome Research Programme
Elizabeth Miller: Department of Infectious Disease Epidemiology London School of Hygiene & Tropical Medicine
Peter McIntyre: University of Otago
Nick Andrews: UK Health Security Agency
Zahin Amin-Chowdhury: UK Health Security Agency
Norman Fry: UK Health Security Agency
Kondwani C. Jambo: Malawi Liverpool Wellcome Research Programme
Neil French: Malawi Liverpool Wellcome Research Programme
Samanta Cristine Grassi Almeida: National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis, Pneumonia and Pneumococcal Infection, Centre of Bacteriology
Shamez N. Ladhani: UK Health Security Agency
Robert S. Heyderman: Malawi Liverpool Wellcome Research Programme
Cheryl Cohen: National Institute for Communicable Diseases of the National Health Laboratory Service
Maria Cristina Cunto Brandileone: National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis, Pneumonia and Pneumococcal Infection, Centre of Bacteriology
Stefan Flasche: London School of Hygiene & Tropical Medicine

Nature Communications, 2023, vol. 14, issue 1, 1-8

Abstract: Abstract Invasive pneumococcal disease (IPD) risk increases with age for older adults whereas the population size benefiting from pneumococcal vaccines and robustness of immunogenic response to vaccination decline. We estimate how demographics, vaccine efficacy/effectiveness (VE), and waning VE impact on optimal age for a single-dose pneumococcal vaccination. Age- and vaccine-serotype-specific IPD cases from routine surveillance of adults ≥ 55 years old (y), ≥ 4-years after infant-pneumococcal vaccine introduction and before 2020, and VE data from prior studies were used to estimate IPD incidence and waning VE which were then combined in a cohort model of vaccine impact. In Brazil, Malawi, South Africa and England 51, 51, 54 and 39% of adults older than 55 y were younger than 65 years old, with a smaller share of annual IPD cases reported among

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-36624-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36624-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-36624-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().